WHO Drug information, Vol. t5. Not 2, 2001
`
`Proposed lNN: List 85
`
`international Nonproprietary Names for
`Pharmaceutical Substances (INN)
`
`
`Notice is hereby given that, in accordancewith article 3 otthe Procedure forthe Selection of Recommended International
`Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under
`consideration by theWorid Health Organization as Proposed international Nonproprietary Names. The inclusion ofa name
`in the lists of Proposed international Nonproprietary Names does not imply any recommendation of the use otthe substance
`in medicine or pharmacy.
`
`- Lists of Proposed (P73) and Recommended (1—35) international Nonproprietary Names can be found in Cumulative List
`No. 9, 1996. The statements indicating action and use are based iargeiyon information supplied by the manufacturer. This
`information is merely meantto providean indication ofthe potential use of newsubstances at thetime they are accorded
`Proposed international Nonproprietary Names. WHO is not in a position eitherto upholdtnese statements orto comment
`on the efficacy ofthe action claimed, Because cftheir provisional nature. these descriptors will neither be revised nor
`included inthe Cumu ative Lists othNs.
`
`Denominations communes internationales
`
`des Substances pharmaceutiques (DCI)
`il est notifié que, contormémentauxdispositions de i‘aiticies de la Procedurea suivre en vuedu choixde Denominations
`communes internationales recommandées pour les Substances pharmaceutiquesles denominations ci-dessous sont
`mises a l’étude parl'Organisation mondiaie de iaSante en tantque denominations communes internationales proposees.
`L'inciusion d'une dénominationdansles listes de DCI proposees n’impiique aucune recommandation envue de i'utiiisation
`de la substance correspondents en médecine ou en pharmaciei
`
`Ontrouvera d’autres listesde Denominations communes internationales proposees (1—73)et recommande’es (1—35)dans
`la Liste récapitu/ati‘ve No. 9, 1996. Les mentions indiquant les propriétes et les indications des substances sontfondees
`suries renseignements communiqués parie tabricanti Eiles ne visent qu‘a donnerune idée de i‘utiiisation potentieile des
`nouveiies substances au moment on elies sont i’objetde propositions de DCi. L’OMS n‘est pas en mesure de contirmer
`ces declarations ni de faire de commentaires sur i‘efficaciié du mode d'action ainsi décriti En raison de leur caractere
`provisoire, ces informations nefigurerontpas dans les iistes recapitulatives de 001.
`
`Denominaciones Comunes lnternacionaies
`
`para las Sustancias Farmacéuticas (DCl)
`De conformidad con lo que dispone ei parrafo 3 del "Procedimiento de Seieccién de Denominaciones Comunes
`lnternacionaies Recomendadas para las Sustancias Farmacéuticas“, se comunica por ei presente anuncio que las
`denominaciones detaliadas en las paginas siguientesestan sometidas a estudio poria Organizacién Mundiaide La Salud
`como Denominaciones Comunes internacronaies Propuestas. La inclusion de Lina denominacio’n en las iistas de las DCi
`Propuestas no supone recomendacion aiguna en favordel empieo de iasustancia respectivaen medicinao en tarmacia.
`
`Las iistas de Denominaciones Comunes lnternacionaies Propuestas (1—73) y Recomendadas (1—35) se encuentran
`reunidas en Cumulative List No. 9: 1996. Las indicaciones sobre accion y uso que aparecen se basan pnncipalmente
`en la informaciér facilitada por los fabricantes. Esta informacién tiene por objeto dar una idea i’micamente de las
`posibiiidades de apiioacién de las nuevas sustancias a las que se asigna una DCi Propuesta, La OMS no esté facultada
`para respaidar esasindicacicnes ni para formuiarcomentarios sobre la et’icaciade la acciénque se atribuye ai producto.
`Debido a su ca racterprovisional, esos datos descriptivos no deben inciuirse en las iistas recapitulativas de DCl.
`
`95
`
`OSI 2018
`OSI 2018
`APOTEX V. OSI
`APOTEX V. OSI
`IPR2016-01284
`
`|PR2016-01284
`
`

`

`Proposed INN: List 85
`
`WHO Drug Information, Vol. 15, No. 2, 2001
`
`Proposed International Nonproprietary Names: List 85
`Comments on, or formal objections to, the proposed names may be forwarded byany person to the [NN Programme of
`the World Health Organization within four months of thedate oftheirpublication in WHODrug Information, i.e., for List
`85 Proposed INN not later than 31 January 2002.
`
`Dénominations communes internationales proposées: Liste 85
`Des observations oudes objections formelles a ['égard des denominations proposées peuventétre adressées parloute
`personne au Programme des Denominations communes mternationalesde l‘Organisation mondiale dela Santé dans un
`délai de quatre mois a oompterde la date de leur publication dans WHO Drug Information. c'est a dire pourla Liste 85
`de DCl Proposées le 31 janvier 2002 au plus tard.
`
`Denominaciones Comunes lnternacionales Propuestas: Lista 85
`Cualquierpersona puede dirigirobservaciones u objeciones respecto de las denominaciones propuestas, al Programa
`de Denominaciones Comunes lnternacionales de la Organizacion Mundial de la Salud, en un plazo de cuatro meses,
`contados desde la fecha de su publicacién en WHO Drug Information, es decir, para la Lista 85 de DCI Propuestas
`el 31 de enero de 2002 a mas tardar.
`
`
`ProposedINN
`(Latin, English, French, Spanish)
`
`Chemical name or description: Action and use: Molecular formula
`Chemical Abstracts Service (CAS) registry number; Graphic formula
`
`00/ Proposée
`
`DCIPropuesla
`
`acidum gadocoleticum
`gadocoletic acid
`
`acide gadocolétique
`
`acido gadocolético
`
`Nom chimique ou description: Propriétés et indications: Fon'nule brute
`Numéro dans Ie regislre du CA S: Formule dé ve/oppée
`
`Nombre quimico o descrmcidn.‘ Accién y uso: Formula empirica
`NL‘Imero de regislro del CA 8: Formula desarrollada
`
`trihydrogen [3fi~[[(4S)—4»[bis[2-[bis[(carboxy-xO)melhyllamino-xMethyllamino-
`KM-A-(carboxy-KowutanoyljaminCJ-1Za-hydroxy-SB-cholan-24-oato(6-)]=
`gadolinate(3»)
`diagnostic agent
`
`trihydrogéno[3B—{[(4S)—4—[bis[2-[bis[(carboxy-KO)méthyl]amino~rcN1éthyI]amino-
`ich-4-(carboxy-x0)butanoyl]amino]-1Zd-hydroxy-SB—cholan-24-oat0(6-)]=
`gadolinate(3-)
`produit é usage diagnostique
`
`trihidrégenoISfl-HM S)-4-[bis[2-[bis[(carboxi-KO)metil]amino-KN}etiflamino-KN}
`4-(carboxi-KO)butanoil]amino]-12a-hidroxi—5B-colan»24—oato(6-))gadolinato(3-)
`agente do diagnésrico
`
`C41HSEGdN4O14
`
`
`
`96
`
`

`

`WHO Drug Information, VOL 15, No 2, 2001
`
`Proposed INN: List 85
`
`afeletecanum
`afeletecan
`
`aféléte’can
`
`afeletecén
`
`alfimeprasum
`alfimeprase
`
`alfiméprase
`
`alfimeprasa
`
`camptothecin, ester with N—[[p»[(3~O-methyI-é—L—fucopyraqosyl)oxy)pheny[;=
`miocarbamoyl}L—histidylxvvaline
`antineoplastic
`
`(2 S)—2—[[(28)—3—(1 H~imidazo{-4-yI)—2—[[[[4—[(3- O-méthyl—ES ~dés oxy—é-L—
`galactopyranosy1)oxy]phényi]amino]thiocarbonyljaminowropanoyl]amino]-
`3-méthylbutanoate de (4S)-4«éthyI—3,14-dioxo-3,4,12,14-tétrahydro-
`1H-pyrano[3'.4’;6,7]indolizino[1,2-b1qumoléin-4-yle
`antine'opia sique
`
`éster de ta camptotecina con MILO-[(3-O—metil~é-L-fucopiranosil)oxi]fenil]=
`tiocarbamoil]-L-histidil-L—valina
`antineoplésico
`
`CdsH‘fiNpfis
`
`215604—75-4
`
`OCH3
`
`CH3 Ho
`
`HO
`
`[S-L-serine]fibrolase-(3-203)-peptide (fibroiase : fibrinolytic enzyme isola‘ed
`from Agkistrodon contn’x contrix venom)
`anfithrombotic
`
`[SALisérine1fibrolase—(3»203)—peptide (fibrolase I enzyme fibrinolyfique extraite
`de venin d'Agkistrodon contrix conm’x)
`antithrombofique
`
`[3-L~serinalfibrolasa-(3-203)—péptido (fibrolasa : enzime fibrinolitica extraida
`de veneno de Agkistrodon conm'x contrix)
`antithrombético
`
`cfiHflinzsoms?
`
`259074—76-5
`
`TKYNGDSDKI
`SICQDLI TVTS
`
`RQWVHQI VNT
`VSHDTLASFG
`
`LVIVADHRl-Il'
`
`S E‘PQRYVQ
`ZNEIY-RPL-N:
` NWRETELLRR
`LAYVGGMCQL
`AIDFDGDTVG
`
`
`l
`KESTGVI‘QDH SAINLLVITWL
`I'EAHELGHNLG MNHDGNQCHC’.‘
`LTVNNPQCIL
`DCSKKDYQTF
`GANSCVMAAI'I
`LSDQPSZ LES
`
`NKF
`
`97
`
`

`

`Proposed INN: ListBS
`
`WHO Drug Information. Vol. 15, No, 2, 2001
`
`alicaforsenum
`alicaforsen
`
`alicaforsen
`
`alicaforseno
`
`a! ilusem um
`alilusem
`
`alilusem
`
`alilusem
`
`2‘-deoxy-(R)vP-thiogu2nylyI-(3’—>5‘)-2‘-deoxy-(R)~P—thiocytidylyI—(3'a5')7
`2’-deoxy«(R)-P—thiocytidylyl-(3‘—>5‘)-2'-deoxy-(R)-P—thiocytidylyl-(3'~~>5‘)-
`2'—deoxy-(R)-P-1hioadenylyl-(3'—a5’)-2'-deoxy-(R)-P-!hioadenylyl—(B‘a5’)—
`2‘»deoxy—(R)7Pithioguanylyl-(3’77>5')-2'-deoxy-(R)—P»!hiocytidylyl-(S'aS‘p
`(R)-P-thiothymidylyl«(3'—>5‘)'2'<deoxy-(R)~P-thioguannyI-(3'—>5‘)-2'-deoxy-
`(R)-P—thioguanyiy!»(3‘a5‘)-2'-deoxy-(R)-P—throcytidyly[-(3‘—>5‘)—2‘-deoxy-
`(R)-P-thioadenylyl-(3'»>5‘)-(R)-P—lhiothymidylyl-(3’—>5')—2'-deoxy-(R)-P-
`lhiocytidyly$—(3">5‘)~2’—deoxy-(R)—P—thiocyfidylyl-(3’a5’)—2'-deoxy-(RH:—
`thioguanyly]-(3’»>5')-(R)—P-thiothymidylyl—(3‘- >5')—2‘-deoxy-(R)»P-thiocytidylyl-
`(3‘95’)—2'-deoxyadenosine nonadecasodium salt
`ant/Sense phosphorotioate oligonucleotide
`
`2'—de'soxy—(R)»P-thioguanylyi-(3’—>5‘)~2'—désoxy«(R)-P-thiocytidylyI-(3'~)5‘)-
`2’—désoxy-(R)~P-thiocytidylyl-(B'eS'yZHdésoxy»(R)«P—thiocytidy|yl»(3‘»5')~
`2’-désoxy-(R)-P-thioadénylyl-(S‘as‘yz'-désoxy-(R)-P-thioadénylyl-(3‘—>5’)—
`2'—désoxy-(R)-P—thioguanylyl-(3'—>5‘)-2‘—désoxy-(R)-P—thiocytidylyI-(395‘)-
`(Ry/12hiothymidylyl~(3'A>5‘)—2'—désoxy-(R)-P-thioguanylyI-(S'i)5')-2‘-désoxy--
`(R)-P-thioguanylyI—(3'->5’)»2’~désoxy-(R)-P-thiocyiidylyI-(3‘~»>5‘)—2'-désoxy~
`(R)-P-thioadénylyi-(S‘afi'ym)-P-thiothymidyly!-(3'—>5‘)-2'—désoxyv(R)-P-
`thiocytidylyl»(3'—>5’)—2’-désoxy-(R)—P-thiocytidylyl<(3'—>5‘)~2‘-dé$oxy»(R)~P~
`1hioguanylyl-(B‘aS')—(R)—P—thiothymidylyI-(S‘as‘)-2’-désoxy-(R)-P-
`thiocytidnyI-(3'65')-2‘-désoxyadénosine nonadécasodique
`inhibiteur de la synthése de la protéine d'adhe’sion [CAM-1
`
`2'—desoxi-(R)—P—tioguaniii[—(3‘95‘)»2’-desoxi—(R)-P-tiocitidilil-(3‘—>5‘)-2‘»desoxi—
`(R)-P—tiocitidilil-(3‘—>5’)-2‘-desoxi-(R)-P—tiocitidili}—(3‘—>5‘)—2'—desoxi-(R)-P—
`tioadenitil-(3'»>5')—2‘-desoxi-(R)-P—tioadenilil-(3‘45’)—2'-desoxi-(R)-P~
`fioguanilili(3'~r>5')»2‘~desoxi—(R)»P7tiocitidilik~(3’~>5')»(R)«P—tiotimidilil-(3’7>5')—
`2'-desoxi-(R)hP—tioguanElil-(3‘—>5’)-2‘-desoxi-(R)-P-tioguanili1-(3'—>5‘)~
`2’-desoxi-(R)—P—tiocitidi1iI-(3‘—>5')-2‘—desoxi~(R)—P-tioadeniIil—(3‘—->5')»(R)-P—
`tiotimidi!il—(3‘—>5’)—2‘-desoxHR)-PvtiocitidiIiI-(3'—>5')-2'—desoxi-(R)-P-tiocitidilil—
`(3‘—>5‘)-2'—desoxi-(R)-P-tioguanilil-(3'~>5')-(R)-P-tiotimidilil-(3'—>5‘)—2'—desaxi-
`(R)-P—tiocitidilil—(3'—>5')-2‘»desoxiadenosina nonadecasédica
`cadena complementan'a (oligonucleétido fosforoz‘ioato)
`
`CMHDSNENawOQEPwSQ
`
`185229-68-9
`
`7-Chloro-1~(2—methylbenzoyI)-2,3-dihydroquinolin~4(1H)-one (E)AO-
`sulfooxime
`diureiic
`
`(B-O-sulfooxime de 7—chloro—1-(2-méthy|benzoyI)—2,3-dihydroquinoléin-
`4(1H)‘one
`diurénque
`
`(B-O-sulfooxima de 7-c!oro—1-(2—meti(benzoil)-2,3-dihidroquinolin-4(1H)-ona
`diurético
`
`
`
`

`

`WHO Drug Information, VOL 15, No. 2, 2001
`
`Proposed INN: L351 85
`
`
`
`17
`7S
`C H CINYOSS
`
`144506-11-6
`
`/SO3H
`
`CH3 0
`
`(+)~(28)—2-[(4,6-dimethylpyrimidin~2-yl):>xy]—3-mathoxy-3,3-dipheny1propanoic
`acid
`endothe/in receptor antagonist
`
`(+)~acide (28)—2-[(4,67ciméthylpyrimidin~2-yl)oxy}A3—méthoxy~
`3,3-diphénylpropano‘fque
`antagonism du récepteur de l’endofhéline
`
`(+)—écido (ZS)-2—[(4,6~dimetilplrimidin~2—il)oxi]—3—metoxi-3,3-difenilpropanoico
`antagonism de/ receptor cle endolelina
`
`CEHIQNZO‘,
`
`177036.944
`
`
`
`Il2R,4R)-4-(2,6-diamino»9H-purin~9»y1)-1.S-dioxolan-2—y21methano]
`antiviral
`
`[(2R,4R)-4<(2.6-diamino-9H—purin-9-yl)-1,3-dioxo‘an-2-y11méthanol
`antiviral
`
`[(ZR:4R)»4-(2,5-diamino-9H-purin-9-ii)~1,3»dioxolan-2-il]metanol
`antiviral
`
`CEHQNEO:
`
`145514.044
`
`NH2
`
`ambrisentanum
`ambrisentan
`
`ambrisentan
`
`ambrisentén
`
`amdoxovirum
`amdoxovir
`
`amdoxovir
`
`amdoxovir
`
`N
`
`N/
`x l
`\>
`N
`NJH
`HO 0%LkO
`
`H2N
`
`H 9
`
`9
`
`

`

`Proposed INN: Us: 85
`
`WHO Drug Information, Vol. 15, No. 2, 2001
`
`
`
`amelubantum
`amelubant
`
`amélubant
`
`amelubant
`
`amotosalenum
`amotosalen
`
`amotosaléne
`
`amotosaleno
`
`bimatoprostum
`bimatoprost
`
`bimatoprost
`
`bimatoprost
`
`100
`
`[[4-[[3-[[4»[1—(4—hydroxyphenyl)»1—rnethylethyl]phenoxy]methyl]benzyl]=
`ethyl
`oxy]phenyl](imino)methyl]carbamate
`leukorriene receptor antagonist
`
`{{4—[[3—[[4~[1-(4-hydroxyphényl)-1—méthyléthyl]phénoxy}méthyl]benzyl]oxy]=
`phényl](imino)méthy[]carbamate d‘éthyle
`antagonists du récepteur des )eucotriénes
`
`[{4-[[3-[{4—[1-(4-hidroxifenil)—1 -metilefillfenoxi]meti1]bencil]oxi]fenil](imino)metil]=
`carbamato de etilo
`antagonism del receptor de leucotn'enos
`
`CK$HMN205
`
`0
`
`NH
`
`HSCAOAN
`
`H
`
`H30 CH3
`
`O O
`
`OH
`
`o/\©/\o
`
`3»[(2—aminoethoxy)methyi]-2,5,B-trimethyl—7H-furo[3,2—g][1]benzopyran-7-one
`photochemical therapy
`
`3-[(2—aminoéthoxy)méthyl]—2,5.9-triméthyl—7H-furo[3,2-g][1]benzopyran—7—one
`photochimiothe’rapie
`
`3-{(2-3minoetoxi)meti1]-2,5,9-trimetil-7H—furo[3,2—g][1 ]benzopiran—7-ona
`rerapia foroqulmica
`
`CWHBNOA
`
`0
`
`HQN/\/
`H3O
`
`161262-29-9
`
`CH3
`\
`o
`
`0
`
`/
`0
`
`CH3
`
`(Z)-7—[(1R,2R,3R,55‘)-3,5-dihydroxy-2-[(1E,38)-3-hydrcxy-5—phenyl-
`1-pentenyl]cyclopentyl]—N—ethyl-5—heptenamide
`antigla ucoma
`
`(Z)-7-[(1R,2R,3R,SS)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phénylpent-
`1-ényl]cyc|opentyI}—N—éthylhept-5-énamide
`antigla ucomateux
`
`(Z)-7—{(1R,2R,3R,58)—3,5-dihidroxi»2—[(1E,3S)-3—hidroxi-S—fenilpent»
`1~enillciclopentil]-N—etilhept—5-enamida
`antiglaucoma
`
`

`

`WHO Drug Information, Vol. 15, No. 2, 2001
`
`Proposed iNN: List 85
`
`06H37N04
`
`155206004
`
`H
`H QHH
`t,-\='/\/\[(NVCH3
`0
`~.
`H OH
`
`
`
`HO’
`
`'
`H H
`
`calda retum
`caldaret
`
`caldaret
`
`caldaret
`
`cipralisantum
`cipralisant
`
`cipralisant
`
`cipralisant
`
`5-methyl-2-(piperazin-1vyl)benzenesultonic acid
`cardiac stimuiant
`
`acide 5-méthyl-2—(pipérazin-1—yl)benzénesulfonique
`cardiotonique
`
`écido 5-metil»2-(p§perazin-1-il)bencenosulfénico
`cardiotdnico
`
`CHH‘BNZOES
`
`133804—444
`
`H30\©: 03H
`N/fi
`K/NH
`
`4»[(1R,2R)-2—(515-dimethylhex—1-ynyl)cyclopropyl]—1H«imidazole
`histamine—H: receptor antagonist
`
`4-[(1R,2R)-2—(5,5»diméthythex»1-ynyI)cycIopropyl]»1H—imidazoie
`antagonists des récepteurs H: de l’histamine
`
`4-[(1R,2R)—2—(5,5-dimeti1hex-‘I—infl)ciclopropiI]-1H—imidazol
`antagonists de 103 receptores H3 de la histamfna
`
`CAK‘HEN2
`
`HH
`
`21 3027-19-1
`
`yfin‘ \
`Sq ; MowHcc CH3
`
`
`101
`
`

`

`Proposed INN; List 85
`
`WHO Drug Information, Vol. 15, N07 2, 2001
`
`
`
`dalbavancinum
`
`dalbavancin
`
`dalbavancine
`
`dalbavancina
`
`5,31-dichIoro-38-de(methoxycarbonyl)-7-demethyi-19-deoxy-56-O-[2-deoxy-
`2-[(10~me1hylundecanoyl)amino]-b-d-glucopyranuronosyl]—38-[[3-
`(dimethylamino)propyl]carbamoyl]—42—O-a~d—mannopyranosyl-1 5-N-
`methyl(ristomycin A aglicone)
`antibiotic
`
`acide Zidésoxy—1—O~[(38,15R,18R,,34R,358,388,48R,503R)«5,31-dichloro-
`38-[[3-(diméthylamino)propyi]carbamoyl]~6,11554,40‘44—pent2hydroxy-42—
`(a-d-mannopyranosyloxy)-1S—(méthylamino)-2,16,36,50,51,59-hexaoxo-
`2,3,16,17.18,19,35,36,37,38,48,49,50,SOa-tétradécahydrov20,23:30,33-
`diéthéno-3,18:35,48—bis(iminométhano)-1H,15H-4,8:10,14:25,28:43,47-
`1étraméthéno-34H-[1,14,6,221dloxadiazacyclooctacosino[4,5—
`m][10,2,16Jbenzoxadiazacyclotétracosén—S€-yl]—2-[(1 0-
`méthylunde‘canoyi)aminol-b-d-glucopyranuronique
`antibiotique
`
`écido 1-O-[(3$,15R,18R,34R,35$,38S,48R,502R)—5,31-dicloro-38-
`[[3-(dimetilamino)propil]carbamoil]-6,11,34,40,44—pentahidroxi—42-
`(u-D-manopiranosiloxi)—15-(metilamino)—2,16,36,50‘51,59—hexaoxo-
`2,3,16,17,18,19,35.36,37,38,48,49,50.503-tetradecahidrO-ZO,23:30,33-
`dieteno-a,18:35,48»bis(iminometano)-1H.15H—4,8:10,14:25,28:43,47»
`telrameteno-34H-[1,14,6,22]dioxadiazaciclooctacosino[4.5—m][10,116]:
`benzoxadiazaciclotetracosen—56»il]‘2-[(10-metilundecanoiI)amino]—2—desoxi—
`{m-glucopiranurénico
`anflbio‘fico
`
`CaeH10905NmOzs
`
`171500—79-1
`
`HO
`
`
`
`
`102
`
`

`

`WHO Drug Information, Vol. 15‘ 14022001
`
`Proposed INN: List 85
`
`darbepoetinum alfa
`darbepoetin alfa
`
`darbépoétine alfa
`
`darbepoetina alfa
`
`{so-LasparagéneSZ-x-thronine,87-1—valina 88-L-asparagine.
`QO-L—threonine]erythropoietin (human)
`ant/anaemi:
`
`[KM—asparagEne,32-L—(hréonme.87—:valine.88«a~asparagine,
`QO-L-thréonine}érythlopoiéiine humalne
`antianémlque
`
`[SO-L-asparagina,32»L~treonina,87-L—va!ina 88—L-asparagina,
`Qoirtreonina}eritropoietina humana
`antia némico
`
`KG 1300 KB 214
`a
`C H
`N O 8.
`
`2098107584
`
`APPRLICDSR VLERYLLEAK EAENITTGCN ETCSLNENIT
`
`SEAVLRGQAL
`VPDTKVNFYA WKRMEVGQQA VEVWQGLALL
`LVNSSQVNET
`LQLHVDKAVS GLRSLTTLLR ALGAQKEAIS
`PPDAASAAPL
`RTITADTFRK LFRVYSNFLR
`C—KLKLYTGEA
`CRTGD
`
`
`
`drotrecoginum alfa
`drotrecogin alfa
`
`drotrécogine alfa
`
`drotrecogina alfa
`
`blood coagulation factor XIV (human)
`anticoagulant
`
`fasteur XIV humain de coagulation sanguine
`anficoagu/anf
`
`factor XIV de coaguiacién sanguinea (humane)
`anticoagulants
`
`103
`
`

`

`Proposed INN: List 85
`
`WHO Drug Information, Vol. 15, No. 2, 2001
`
`315.
`581
`640
`d1
`cmH (N o s,
`
`98530-76—8
`
`FQNVDD‘LAF
`
`lCDFJJAKJI
`ANSFLJJLRH SSLJRJCIJJ
`r—”——*“——~‘F::::::;-———1
`l___—_—l
`LVLPLEHPCA SLCCGHGTCI BGIGSFSCDE
`WSKHVDGDQC
`a r-__—\
`l
`RSGWEGRFCQ REVSFLNC SL
`DNGGCTHYCL
`EEVGWRRCSC
`I
`.
`CGRPWKRMEK KRSHL
`
`APGYKLGDDL
`
`LQCHPAVKFP
`
`DTE
`KKKLACGAVL
`S PWQVVLLDS
`IDGKMTRRGD
`DQEDQVDPRL
`I.._—_.__...—___l
`:HPSWVLTAA HCMDESKKLL VRLGEYDLRR WEKWELDLDI
`-—\
`KEVFVHPiTYS KSTTDNDIAL
`LHLAQPA‘I‘LS QTIVPICLPD
`SGLAERELNQ AGQE’l‘LV'l‘GW GYHSSREKEA
`KRI‘VRTFVLNF
`*
`r’~—"fi
`IKIPVVPHNE
`CSEVMSNMVS
`ENMLCAGILG
`DRQDACEGDS
`r__..—1
`GGPM’VASFHG
`TWFLVGLVSW GEGCGLLHNY GVYTKVSRYL
`
`DWIHGHIRDK EAPQKSWAP
`
`* glycosylation sites
`' sites de glycosylatl'on
`* posiciones de glicosilacién
`
`HO
`
`B = ___N
`H
`
`CO2H
`H
`.'
`
`o
`
`H020
`
`cogH
`
`H
`
`4
`
`J : __N
`H
`
`o
`
`1~[(52.7E,208)-‘la,3B-dihydroxy-9,10»secochola-5,7,10(19)-trien-
`24-oyljpiperidine
`antipsoriaflc
`
`1-[(52,7E.20$)-1a,3B-dihydroxy-9,10-sécochota-5,7,10(19)-trién-
`24—oyl]pipéridine
`antipsoriasiq ue
`
`1—[(52,7E,208)-1a,3fi-dihidroxi-9,10—secocoIa-5,7,10(19)-trien~
`24-oil]piperidina
`antipsoriésico
`
`ecalcidenum
`ecalcidene
`
`écalcidéne
`
`ecalcideno
`
`104
`
`

`

`WHO Drug lnformallon. Vol. 15, No. 2, 2001
`
`Proposed lNNl Lis: 85
`
`CZSHéNOS
`
`1503 37-94-13
`
`
`
`immunoglobulin Gl, antl-(human antigen C01 ‘1 a) (numan—mouse monoclonal
`hu112471—Chain), disulfide watn human—mouse monoclonal hu1124 light
`chain= dimer
`immunomodulator
`
`immunoglobuiine 61: anti-(antigéne (301 la humain) (chalne 3'1 de l’anticorps
`moclonal de souris humanisé hu1124),dimére du disulfure avec la cl‘a‘me
`Iégére de I’anlicorps moclonal de souris humanisé hu1124
`immunomoduiateur
`
`inmunoglobulina G1: anli-(antigeno CDMa humane) (cadena 3/1 del antlcuerpo
`monoclonal humanizado de ratén hu1124), dimero del disulfuro con la
`cadena ligera del anticuerpo monoclonal humanizadc de ratén hu1124
`inmunomodulador
`
`214745434
`
`acelyl-L—tyrosyl-L—lhreonyI-L~seryl»L-Ieucyl-;-isoleucyI-L-hlstidyl—L—seryl-
`L-leucyl-L-isoleucyl—L-a-glutamy[vL-a—giutamyl-L—seryl-L-glutaminyi-
`L-asparaginyl—L—glulaminyl»L-glutaminyl-Lfl-glulamyl»L—‘ysyl—L-asparaginyl—
`L—a-glutamy|-L-g[utaminyl-L-u—glutamyl»L-leucyl-L-leucyl-L~a.-glulamyl-L-leucyl‘
`L-a-aspa’lyl-L—lysyl-L-tryplophy[«L-aIanyl-L-ser/l-L-leucyl-L-tryptophyl-
`L»asparaginyl»L-tryptophyl-'_-pnenylalaninamide
`antiviral
`
`acétyl—L-lyrosyl-L-thréonyl-L-séryl-L—leucyl-L-isoleucylibhlstidyl—L-séryl-
`L-leucyl—L-isoleucyI—L-u-giutamyl-L-a-glutamyl-L-séryl-L-glutaminyl—
`L~asparaginyl-L—glutaminyl-L—g[utamlnyl-L-a—glutamyl—L—lysyI-L-asparaginyl-
`bot—9lukamyl-L-glutamlnylegg!ulamyI—L-leucyl—L—leucylALiaiglutamylibleucyL
`L-a-aspartyl-L-lysyl-L~tryptophyl-L-alanyl~L—séryl—L—leucyl-L-tryptophyl—
`L-asparaginyl-L-tryptophyl-;-pnényla!anlnamlde
`antiviral
`
`acetil-L-tfrosil-L-lreonil-L-seril‘L-leUCIl-L~lsoleu:El-L—hlstidi[~L—senl-L-leucll-
`L~isoleucil-L-a-glulamil-L—u—glulamll-;—seril-L-g1ulaminil-L-asparaginiI—L—glutaminil—
`L-glulaminil~L~a~glulamil—_<lisll—a.—asparaginii-L‘mglutamil-L—glutaminil-mx-gIutamil»
`L-leucil—Heu cilich-glulaml »_-leucli»;-a~asparéil—L-lisiLL~trlptofll»L—alanil-L-serlli
`L-leucil~Lalriptolil-;»asparaginil—L~i!2p:of§l-L—fenflalaninamlda
`antiviral
`
`105
`
`efalizumabum
`efalizumab
`
`éfaiizumab
`
`efalizumab
`
`enfuvirtidum
`enfuvimde
`
`enfuvirtide
`
`enfuvlrtlda
`
`

`

`Proposed INN: ListBS
`
`WHO Drug Information, VoL 15, No, 2, 2001
`
`
`
`516‘
`cmeN o
`
`159519-650
`
`H C
`\fl—Tyr—Thr—Ser—Leu—He—His-Ser—Leu—He—Glu—G|u—-Ser—
`a
`O
`10
`Gin—ASH—Gln-—G|n—Glu~Lys-Asn—Glu—Gln-—Glu——Leu—Leu—Glu—
`20
`Leu—Asp—Lys—Trp —AIa—Ser—-Leu'—Trp~Asn —Trp —Phe -NHg
`30
`
`2»acetyl—1~alkyI-sn-g[ycero—3-phosphocholine deaoetylase7(67400)rpeptide
`(human)
`antiaflergic, antiasthmatic
`
`désacélylase—(6-400)-peplide (humaine) de la Z-acétyM-alkyI-sn-glycéro«
`3—phosphocholine
`anfiallergique, antiasthmatique
`
`1—0—anui|~2—acet1l-sn-glicero-3-fosfocolina 6-400-desacetilasa (humana)
`antialérgico, anliasmatico
`
`13
`3107
`545
`53s
`thH N O S
`
`14
`
`208576-22—1
`
`PRGNGPYSVG CTDLMFDHTN KGTFLRLYYP
`AAASFGQTKI
`SQDNDRLDTL WIPNKEYFWG
`LSKFLGTHWL MGNILRLLFG
`SMTTPANWNS
`PLRPGEKYPL
`VVFSHGLGAF RTLYSAIGID
`
`EIGDKSWLYL
`TYYFKDQSAA
`LASHGFIVAA VEHRDRSASA
`LDIDHGKPVK
`RTLKQEEETH IRNEQVRQRA KECSQALSLI
`NALDLKFDME QLKDSlDREK IAVIGHSFGG ATVIQTLSED
`QRFRCGIALD AWMFPLGBEV YSRIPQPLFF
`INSEYFQYPA
`NIIKMKKCYS
`PDKERKMITI
`RGSVHQNFAD
`FTFATGKIIG
`
`GLHKDFDQWD
`HMLKLKGDID SNVAIDLSNK ASLAFLQKHL
`CLIEGDDENL
`IPGTNINTTN QHIMLQNSSG IEKYN
`
`1-165-erythropoietin (human HMR4396), glycoform 5
`antianaemic
`
`1~165~érythropoiétine (humaine HMR4395)| glycoforme 8
`antianémique
`
`1-165-eritropoietina (humana HMR4396), glicoforma 5
`ant/anémico
`
`epafipas um
`epafipase
`
`épafipase
`
`epaflpasa
`
`epoetinum delta
`epoefin delta
`
`époétine delta
`
`epoetina delta
`
`106
`
`

`

`WHO Drug Information, Vol, 15. No. 2, 2001
`
`Proposed INN: List 85
`
`
`
`erlosamidum
`eriosamide
`
`erlosamide
`
`erlosamicla
`
`erlotinibum
`erlotinib
`
`erlotinib
`
`erlotinib
`
`5
`CsaeH1s-31 N23024OS
`
`261356—8043
`
`
`
`Z‘IKRI‘IEVGQQA
`LQLHVDKAVS
`RTI TADTE‘RK
`
`
`[——
`EAEiIITTGCA 7315C SLNEIK’I T
`SEAVLRGQAL
`ALGAQKEAIS
`GKLKLY‘I’GEA
`
`
`
`’ : glyccsylation sites 5 sizes de glycosyiafion :' posicicnes c‘e gricosilaslén
`
`(2R)-Z-(acetylamino)-N-benzyl—3-'nethoxypmpanamide
`anticonvu/sant
`
`(2R)-2~(acétylamino)-N~benzy1—3—méthoxypropanamide
`anticon vulsivanf
`
`(2R)—2A(acetilamino)-N»benc1l-3-metoxipropanamida
`anticon vulsivo
`
`cfiHfiNzoz
`
`175481-364
`
`N—(S-ethynylphenylrs:77bis(2»methoxyeihoxy)quinazolin—4—amine
`ant/neoplasm
`
`N~(3—éthynylphény[)-6:7-bis(2—méthoxyéthoxy)quinazoiin-A—amine
`antinéoplasique
`
`N-(3-etiniifeni|)-6.7-bis(2-metoxieioxi)quinazoiin-4<amina
`antineoplésico
`
`CZHZNSOL
`
`183321—7443
`
`HEC\O/\/C / I
`HcC/O\/\C \
`*
`
`N\W
`/ N
`
`CH
`
`w!l//
`
`
`107
`
`

`

`Proposed INN: List 85
`
`WHO Drug Information, Vol, 15, No‘ 2, 2001
`
`
`
`febuxostatum
`febuxostat
`
`febuxostat
`
`fe buxostat
`
`feloprentanum
`feloprentan
`
`féloprentan
`
`feloprentén
`
`finafloxacinum
`finafloxacin
`
`finafloxacine
`
`finafloxacina
`
`108
`
`2»[3—cyan0-4—(2-methylpr0poxy)phenyl]—4-methy!thiazoIe-S-carboxylic acid
`xanthine oxidase and xanthine dehydrogenase Inhibitor
`
`acide 2-[3—cyano—A-(Z‘méthylpropoxymhényl]‘4-méthylthiazole—
`5-carboxy9ique
`inhibiteur de la xanrhine oxydase et de la xanthine déshydrogénase
`
`écido 2-[3«ciano—4—(2—metilpropoxi)feniI]—4-metiltiazol-5-carboxilico
`I'm/libidor de la oxidasa de xanlr'na y la deshidmgenasa de xanh‘na
`CEH16N2038
`144060—537
`
`CH3
`
`7\s
`
`cogH
`
`HC
`3\|/\OCH3
`
`CN
`
`(28)-3—[2—(3,4-dimthoxyphenyI)ethoxy]—2-[(4,6»dimethylpyrimidin—Z—yl)oxy]—
`3.3-diphenylpropanoic acid
`endothelin receptor antagonist
`
`acide (23)-3—[2-(3,4-diméthoxyphényl)éthoxy]-2—[(4,6-diméthylpyrimidim
`2-yl)oxy]‘3‘37diphénylpropano‘l'que
`antagonisfe du récepteur de I’endothéline
`
`écido (2S)-3~[2~(3.4—dimetoxifenibetoxi]-2-[(4,6.dimetilpirimidin~2~il)oxi]—
`3.3~difenilpropanoico
`antagonists! d9! receptor de endote/ina
`31.210
`C H NO.
`
`204261334
`
`
`
`(—)-8~cyano-1-cyclopropyl~6-fluoro-7-[(AaS,7aS)-hexahydropyrrolo[3,4-b]-
`1,4—cxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-a-carboxylc acid
`antibacterial
`
`(—)-acide 8-cyano-1~cyclopropyI-6~f]uoro—7—[(4aS,7aS)»
`hexahydropyrrolo[3,4«b]—1,4-oxazin‘6(2H)~yI]-4—oxo-1,4-dihydroquinoléine—
`Sicarboxyfique
`antibactérien
`
`(-)-écido 8-ciano-1—ciclopropi1-6-fluoro-7-[(4aS,7aS)-hexahidropirro|o[3,4-b]-
`1,4-oxazin-6(2H)-iI)-4-oxo-1,4~dihidroquinoiina-3-carboxilico
`antibacteriano
`
`

`

`WHO Drug information, Vol. 15, No, 2‘ 2001
`
`Proposed INN: List 85
`
`209342—40—5
`
`gadomelitolum
`gadomemol
`
`gadomélitol
`
`gadomelitol
`
`hydrogen [2,2’,2”,2”’»[1,4,7,1O-tetraazacyclododecan94.4‘7,1O—triyl]tetrakis=
`[5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2SI3R,4R,5R)-2,3,4,5 ,6—pentahydroxyhexyl—
`2,4,6-tribrom01carbamoynphenmamino]—2—oxoetfyl]carbamoprhenyl]:
`carbamoyl]phenyUamino]—2-oxoethyl}ammo]-S-oxopentanoato](4~)]=
`gadolinate(1—)
`diagnostic agent
`
`hydrogéno-[2.2',2”.2‘”-[1 4.7 10-Zétraazacyclododécane~1,4‘7,10-lriyl]tétrakis
`[5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2S.3R.4R¢5R)—2,3,4,5,6~peht3hydroxyhexyl-
`2,4,6—tribromolcarbamoyuphényl]amino}»2»oxoéthyl]carbamcyUphényt]:
`carbamoyl]phényl]amina]»2-oxoéthyl]amino]~5-0xopentanoato](4-)]=
`gadolinate(1—)
`produit a‘ usage diagnosiique
`
`hidrégeno-[Z,2"2“:2'“-[1,4],10~tetraazaciclododecano—1,4,7,10-triil]tetrakis=
`[5—[I2—[[4-[[4—[[2-[[3,5—bisfbis[(2S,3R,4R:5R)-2:3,4,5,6-pentahidroxihexil»
`2,4,6»tribromo]carbamoinenanminoj-Z-oxoet3110arbamoinenil]carbamoil}fenil]=
`amin0172ioxoetiHamino]«570xopentanoato]{4—)}gado!xnato(1 -)
`agente de diagno'srico
`
`C§5H313 BrfiGdNEQO‘nE
`
`R
`
`R
`
`‘ozc/kNmecog
`\ x
`1 em1 \
`N\
`/N
`\(R
`2/
`
`2
`00 '
`
`2
`HO c
`
`C
`
`‘
`HN
`O
`
`l
`
`NH
`
`(g0
`H20
`\
`
`QH
`
`OH
`
`OH
`
`OH
`
`
`
`
`109
`
`

`

`Proposed INN: List 85
`
`WHO Drug Information, Vol. 15, No‘ 2, 2001
`
`garnocestimum
`gamocestim
`
`garnocestim
`
`garnQCestim
`
`gefitini burn
`gefitinib
`
`géfitinib
`
`gefitinib
`
`ingliforibum
`ingiiforib
`
`ingliforib
`
`ingliforib
`
`5-73—macr0phage inflammatory protein 20. (human gene groZ)
`immunomodu/ator
`
`CXC chimiokine GROB-(5-73)-peptide (GROfi : protéine inflammatoire humaine
`sécrétée par les macrophages)
`immunomodulateur
`
`CXC quimiokina GROB—(5773fpépfido (GROB :proteine inflamatoria humane
`secretada por los macréfagos)
`inmunomodulador
`325
`3:7
`9?
`C H N 03536
`
`246861—964
`
`I——’_‘"‘_—"——_~—‘1
`
`TELRCQ
`IATLKNGQKA
`
`PGPHCAQTEV
`$LQTLQGIHL KNIQSVKVKS
`CLNPASPMVK KIIEKMLKNG KSN
`
`N-(3—chIoro—4-fluorophenyl)-7-methoxy-B-[3—(morpholin-
`4~yl)propoxy]quinazoiin»4-amine
`anfineoplasfic
`
`N-(3—chIoro—4-f1uorophényl)-7-méthoxy»6-[3-(morpholin-
`4»yl)propoxy]quinazo]in-4~amine
`antméoplasique
`
`N-(3-cloro—4-fluorofenii)-7-metoxi-6—[3—(morfolin-4-il)propoxi]quinazolin-
`4-amina
`ant/neopla'sico
`
`CZZHZpIFNI‘O3
`
`1 84475—35-2
`
`H300
`
`r/‘\N/\v/\O
`o\/I
`
`N
`\W
`/N
`mamF
`
`5»ch|oro-N-((1S,2R)»1-benzy[-3-(cis-3x4-dihydroxypyrrolidin-1-y|)-
`2-hydroxy»3—oxopropyI]-1H—IndoIe—Z—carboxamide
`ant/diabetic
`
`5-chloro-N-[(1S,2R)-1-benzyI-3-(cis-3,4-dihydroxypyrrolidin-1—yI)-
`2-hydroxy-3-oxopropyl]—1H—indoIe-Z-carboxamide
`antidiabétique
`
`‘
`
`5-Cl01’O-N-[(1 S,2R)-1-bencil-B-(cis-S,4-dihidroxipirrolldin-1~i|)-2«hidroxi-
`3-oxopropiII-1H—indoI-Z-carboxamida
`anfidiabélico
`
`
`110
`
`

`

`WHO Drug Information; Vol. 15, No.2. 2001
`
`Proposed lNN: List 85
`
`ipravacainum
`ipravacaine
`
`ipravaca‘l'ne
`
`ipravacaina
`
`isegananum
`iseganan
`
`iséganan
`
`lseganan
`
`cargowoe
`
`156392-654
`
`
`
`(ZRSH—(cyclopropylmethyl)»2‘,6’~dimethyl-2-piperidinecarboxanilide
`local anaesthetic
`
`(ZRSH .(cyclopropylmélhyl)-N-(2=6~diméthy|phény[)pipéridine—Z—carboxamide
`aneslhésique local
`
`(ZRSH -(ciclopropilmetil)»N—(2.6-dimetiIfeniOpiperidina-Z-carboxamida
`anesrésioo local
`
`QGHZNZO
`
`1661816391
`
`CH3
`
`H H
`N
`
`“
`
`N
`
`CH
`
`I
`and enamlomer
`91 énan‘iomére
`y enantiOmero
`
`L-arginylglycylglycyI-L»leucyl-L—cysteinyI—L-tyrosyliucysieinyliLiarginylglycyli
`L-arginyl-L-phenylaIanyI-L-cysteinyl—L—valyl~L-cysteinyl-L—valylglycyl-
`L-argininamide cyclic (5—)14)‘(7->12)-bis(disulfide)
`antibacterial
`
`(5a14),(7—>12)7bis(disulfure cyclique) de L-arginyligchyi»glycyl»L~|eucyl—
`L-systéinyI-;~lyrosyle-cystéinyi-L-arginyl-glycyH-arginyl-L-phénylalanyl-
`L—cystéinyl-L-valyl-L-cystéinyl-L—valnglycyl—L-argininamide
`antlbactérien
`
`(5—)14)‘(7—>12)—bls(d|su1furo ciclico) de L-argInil~glicil-gIICil-L—Ieucil-L~cisteinil-
`L-tirosiI»L-cisteinilearginil»glch-_-arginil-L—fenilalanil—L—cisteini[-L~valil-L-cisteinil-
`Liva‘iI—glicil-L—argininamida
`anilbacz‘en‘ano
`
`111
`
`

`

`Proposed INN; List 85
`
`WHO Drug Information, Vol. 15, No‘ 2, 2001
`
`
`
`73126
`c H Nmowsd
`
`257277-057
`
`H—Arg——GIy—Gly—LeJ—Cys—Tyr#Cys —Arg—Gly—Arg—Phe—Cys!
`l_____.____l
`
`Val—Cys—Val—Gly—Arg—NH2
`
`immunoglobulin G. anli—(human carcinoembryonic antigen) (human-mouse
`monoclonal hMN—M y-chain)‘ disulfide with human-mouse monoclonal
`hMNvl4 K-chain, dimer
`immunomoduiator
`
`immunoglobuline G, anti-(antigéne carcinoembryonnaire humain) (shame-y de
`l’antlcorps monoclonal de souris humanisé hMN-14), dimére du disulfure avec
`la chaine~x de l‘anticorps monoclonal de souris humanisé hMN-14
`immunomodulateur
`
`inmunoglobulina G, anti»(antl’geno carcinoembrionario humane) (cadena—y del
`anticuerpo monoclonal humanizado de ratén hMN—14), dimero del disulfuro
`con la cadena-K del anticuerpo monoclonal humanizado de raton hMN-M
`inmunomodulador
`
`219649»O7—7
`
`methyl 6,11-dlhydro-11-[l-[2-I4-(—2—quinolylmethoxy)phenyl]ethyl]—
`4-piperidinylidene]-5H—imidazo{2,1-b][3]benzazepine-B—carboxylate
`antineop/astic
`
`11-[1-[2—[4—(quinoléln—Z-ylméthoxy)phényl]éthyl]pipéridin-4-ylldéne]—
`6,11—dihydro-5H-imidazol2.1—b][3]benzazéplne-3-carboxylate de méthyle
`antinéoplasique
`
`11-[1-[2-[4-(quinolin—2-ilmeluxi)leniljetillpiperidin-4-lliden01-6,11-dihidro-
`5H-imidazo[2,1-b][3]benzazepina-3—carboxllalo de metilo
`antineop/ésico
`
`labetuzumabum
`labetuzumab
`
`labéluzumab
`
`labetuzumab
`
`laniquidarum
`lanlquidar
`
`laniquidar
`
`lanlquidar
`
`112
`
`

`

`WHO Drug Information, Vol. 15, No. 2, 2001
`
`Proposed INN: List 85
`
`
`
`CEHiNLO:
`
`197509-468
`
`lapisterid um
`lapislaride
`
`lapistéride
`
`lapisterida
`
`[aquinimodum
`Iaquinimod
`
`laquinimod
`
`laquinimod
`
`N-[1»(4-methcxypheny!)-1-me2hylethyl}3—cxo»4-aza-5a-andrest-1-ene—
`17B.carboxamide
`5é-reductase inhibitor
`
`3-(1vbenzy}p|péridin»4-yl)-1-(2:3,415-téirahydro-1H.1-benzazépin-
`8-yl)propan—1-one
`inhibiteur de la 5é-re'ductase
`
`3-(1-benci[piperidin-4~ii)»1—(2,3.4,5-tetrahidro-1H-1-benzazepin-8-il)propan-
`1-ona
`inhibidor de la 5é—reductasa
`
`8-“?
`C H N 3
`
`1421394504
`
`
`
`S-chlororNiethyl»4-hydroxy—1-methyl-2—oxo-N—phenyl~1,2-dihydroquinoline-
`3-carboxamide
`immunomodulator
`
`5-chIoro~NAéthyI-4-hydroxy-1-mélhyl-2—oxc-N-phényl-1,Z—dihydroquinoléine-
`3~carboxamide
`immunomodu/ateur
`
`5—cloro—N-etiI-4-h>droxi-1»meti|—2—0X07NrfeniE-1,2—dihidroquinolina—
`3-carboxamida
`inmunomodulador
`
`
`113
`
`

`

`Proposed tNN: List85
`
`WHO Drug Information. Vol. 15, No. 2, 2001
`
`owl-avoswzo3
`
`248281-84—7
`
`laronidasum
`laronidase
`
`laronidase
`
`laronidasa
`
`B-L—histidinea-L-iduronidase (human)
`enzyme
`
`[8-L-histidine1—a-L-iduronidase humaine
`enzyme
`
`B-L-hisiidina—a»L-iduronidasa (humano)
`enzima
`
`31w 4&4
`90‘
`BM 12
`C.
`.H 7N O S
`
`210589—09—6
`
`AEAPHLVHVD AARALWPLRR
`LSWDQQLNLA
`YVGAVPHRGI
`
`FWRSTGFEEF
`KQVRTHWLLE
`
`LPHSQADQYV
`LVTTRGSTGR
`
`LLPGFELMGS ASGHFTDFED
`GLSYfiFTHLD GYLDLLRENQ
`KQQVFEWKDL VSSiARRYIG RYGLAHVSKW NFETWNEPDH
`
`HDFDfiVSMTM QGFLNYYDAE*_SEGLRAASPA LRLGGPGDSF
`HTPPRSPLSW GLLRHEEPGT NFFTGEAGVR
`LDYISLHRKG
`ARSSISILEQ EKVVAQQIRQ
`LFPKFADTPI
`YNDEADPLVG
`
`VTYAAMVVKV
`WSLPQPWRAD
`LSNDNAFLSY HPEPFAQRTL
`VLTAMGLLAL
`LDEEQLWAEV
`RPQGPADAWR AAVLIYASDD
`
`IAQHQNLLLA fiTTSAFPYAL
`TARFQVfiNTR
`PPHVQLLRKP
`SQAGTVLDSh HTVGVLASAH
`TRAHPfiRSVA VTLRLRGVPP
`
`PTAEQFRRMR
`EWRRLGRPVF
`LDNGLEEFDG
`GPGLVYVTRY
`LLVHVE§§PE
`LRPALRLPSL
`RPLPAGGRLT
`AAEDPVAAAP
`LVWSDEHVGS KEEFTYEIQF
`KPPGQVTRLR ALPLTQGQLV
`SQDGKAYTPV
`SRKPSTFNLF VFSPDTGAVS
`GSYRVRALDY
`WARPGPFSDP VPYLEVPVPR GPPSPGNP
`
`‘ : glycosyiation sites lsites de glycosylation / posiciones de glicosilacién
`L» : disulfide / disutfure / disulfuro
`
`
`114
`
`

`

`WHO Drug Information, Vol 15, No. 2, 2001
`
`Proposed INN: List 85
`
`Ilrimilastum
`lirimilast
`
`lirimilast
`
`lirimilast
`
`livaraparinu m calcium
`livaraparin calcium
`
`Iivaraparine oalcique
`
`livaraparina calcica
`
`2-(2,4-dichlorebenzoyll>3~ureidobenzofuran-S-yl methanesulfonate
`anriasthmatic
`
`méthanesulfonate de 2-(2,4-dicnlorobenzoyl)-3-ureidabenzoturanAB—yle
`antiasthmatique
`
`metanesulfonato de 2-(2,4—diclornbenzoil)-3-ureidobenzofuran-o-ilo
`antiasma tico
`
`C‘iTH‘iZClZNZOSS
`
`N
`
`I
`
`
`
`O//J\
`
`NH2
`
`calcium salt of a low molecular mass heparin that is obtained by nitrous acid
`depolymenzation of heparin from porcine intestinal mucosa; the majority of
`the components have a 2-O~sulto-a-L-idopyranosuronic acid structure at the
`non-reducing end and a 6-O-sulfo-struoture at the reducing end of their
`chain; the mass-average molecular mass ranges between 3000 and 5000
`with 75% is iess than 8000; the degree of sulfatation is approximately 2 per
`disaccharidic unit
`anticoagulant
`
`sel oalcique dtune heparine de basse masse molteoulaire obtenue par
`dépolymérisation, au moyen d‘acide nitreux. d’héparine de muqueuse
`intestinale de porc; Ia majorite' des composants de la livaraparine calclque
`possedent une structure acide 2»O—sulfo<a-L—idopyranosuronique a
`l’extrémite non reductrioe de leur chaine et une structure 6-O-sulfatée a
`l‘extrémite réductrice de leur chaine ; la masse moléculaire relative moyenne
`est de 3000 a 5000, 75% étant inte'rieur a 8000; lo degré de sulfatation par
`unite disaccharide est voisin de 2
`anticoagulant
`
`sal calcica de una heparina de baja masa molecular obtenida cle heparina de
`mucosa intestinal de cerdo por despolimerizacién con acido nitroso la
`mayoria de Ios componentes de la livaraparina caloica tienen acido 2-O-
`suIfo-a-L-idopiranosuronico en el extreme no reductor de la cadena y una
`estructura 6—O»sulfatada en el extreme reductor de la cadena; la masa
`molecular relative me dia es de 3000 a 5000, s